Poly ICLC
(verify) Endogenous
Exogenous
Poly ICLC is an immunostimulant. It is polyinosinic-polycytidylic acid (poly I:C) mixed with the stabilizers carboxymethylcellulose and polylysine.[1] It is under trial for use in cancer.[2]
Poly I:C is a ligand for toll like receptor-3, which usually triggers on the structurally similar double-stranded RNA present in some viruses.[1]
References
- ^ a b Zhu X, Nishimura F, Sasaki K, et al. (2007). "Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models". Journal of Translational Medicine. 5: 10. doi:10.1186/1479-5876-5-10. PMC 1802742. PMID 17295916.
- ^ "Intervention Dynamic Trial Listing Page". National Cancer Institute. 13 June 2017.
External links
- National Cancer Institute: poly ICLC
- v
- t
- e
Immunostimulants (L03)
Cytokines |
| ||||||
---|---|---|---|---|---|---|---|
Other protein / peptide | |||||||
Other |
- beta-glucan
- heterocyclic compound
- hydroxyquinoline
- Mifamurtide
- oligopeptides
- polyribonucleotide
- Polyinosinic:polycytidylic acid
- thiazolidine
- Inosine pranobex
- vaccines
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e